Research programme: polycystic kidney disease therapy - Sanofi
Alternative Names: Polycystic kidney disease therapy research programme - SanofiLatest Information Update: 31 Mar 2022
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Polycystic kidney disease
Most Recent Events
- 31 Dec 2010 No development reported - Preclinical for Polycystic kidney disease in USA (unspecified route)
- 30 Apr 2006 This programme is still in active development
- 29 Jul 2003 Genzyme General, Genzyme Biosurgery and Genzyme Molecular Oncology are now called Genzyme Corporation